<DOC>
	<DOCNO>NCT00275821</DOCNO>
	<brief_summary>The study test efficacy safety alternative dose regimen effective monthly injection .</brief_summary>
	<brief_title>Efficacy Safety Ranibizumab Patients With Subfoveal Choroidal Neovascularization ( CNV ) Secondary Age-related Macular Degeneration ( AMD )</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Choroidal Neovascularization</mesh_term>
	<mesh_term>Neovascularization , Pathologic</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Patients primary recurrent subfoveal CNV secondary AMD , include predominantly classic , minimally classic occult lesion classic component Patients BCVA score 73 24 letter , inclusively , study eye use ETDRSlike grade chart ( approximately 20/40 20/320 ) Prior treatment study eye verteporfin , externalbeam radiation therapy , subfoveal focal laser photocoagulation , vitrectomy , transpupillary thermotherapy . History submacular surgery surgical intervention AMD study eye , glaucoma filtration surgery , corneal transplant surgery . Laser photocoagulation ( juxtafoveal extrafoveal ) study eye within one month precede Baseline . Other protocoldefined inclusion/exclusion criterion apply study .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>Age-related macular degeneration , ranibizumab</keyword>
</DOC>